HOLLISTER, Calif. - Alpha Teknova, Inc. (NASDAQ:TKNO), a key supplier of reagents for pharmaceutical development, announced its preliminary financial results for the second quarter ended June 30, 2024, today. Despite a decline in total revenue compared to the same quarter last year, the company upheld its 2024 revenue guidance of $35-38 million.
The company's total revenue for the second quarter is estimated to be between $9.4 and $9.6 million, marking a 17% to 18% decrease from the second quarter of 2023. However, after adjusting for an unusually large Clinical Solutions order from the previous year, the revenue reflects an increase of 7% to 9%.
Teknova's customer base remains diverse, with no individual direct customer accounting for over $1.0 million in year-to-date revenue. The company also highlighted its cost management successes, including a significant reduction in headcount by over 40% since the second quarter peak of 2022, leaving 169 associates currently on staff.
Despite the revenue decrease in the Clinical Solutions category compared to the previous fiscal year, Teknova has increased its customer base from 34 to 43 since 2023. The company attributes this to a growing demand for its GMP-grade products as cell and gene therapies advance through clinical trials.
In the Lab Essentials division, Teknova has improved customer experience and manufacturing efficiency, resulting in the highest on-time delivery rates for both made-to-stock and made-to-order products. The number of Lab Essentials customers has grown from 2,829 to 2,913 since last fiscal year.
Teknova also reaffirmed its expectation for Free Cash Outflow to be under $18 million for the year, with $3.0 to $3.4 million utilized in the second quarter.
The company is scheduled to release its complete financial results for the second quarter on August 13th, 2024, after the market closes. The preliminary results are based on currently available information and have not yet been fully reviewed or audited.
This financial update is based on a press release statement from Teknova. The company's forward-looking statements about its financial performance and business prospects are subject to various risks, including market demand and global economic uncertainties. Teknova does not undertake any obligation to update these statements unless required by securities laws.
In other recent news, Teknova reported a 2% year-over-year increase in revenue for the first quarter of 2024, marking a solid start to the year. The company also noted an 18% sequential improvement in revenue from the fourth quarter of 2023. This performance was attributed to a diverse customer base and the introduction of new products such as the AAV-Tek AAV Stabilizer and Build-Tek.
Teknova's cost management strategies led to a $2.3 million improvement in adjusted EBITDA compared to the previous year. The company reiterated its revenue guidance for 2024, expecting to achieve between $35 million and $38 million.
In other developments, Teknova's new facility is operational and contributing to revenue. The company expects a stronger market environment in early 2025, supported by the Clinical Solutions segment's 7% revenue increase.
Despite a reduction in the workforce by 31% from the previous year, aggressive expense management is projected to generate savings of approximately $8 million by Q2 2024. Lastly, three cell and gene therapy customers are entering Phase III clinical trials later this year, with commercialization expected in late 2025 to 2026.
InvestingPro Insights
Alpha Teknova, Inc. (NASDAQ:TKNO) seems to be navigating through a challenging period, as indicated by the preliminary financial results for Q2 2024. While the company maintains its revenue guidance, a closer look at the real-time data from InvestingPro reveals some critical aspects investors should consider.
The market capitalization of Teknova stands at a modest $49.8 million, reflecting the small-cap nature of the company. This could imply a higher risk and potential for volatility, which is also suggested by the stock’s significant price decline over the last six months, dropping by 68.37%. Furthermore, the company’s Price / Book ratio for the last twelve months as of Q1 2024 is 0.6, indicating that the stock may be undervalued relative to its assets.
One of the InvestingPro Tips highlights that the company's stock is currently trading near its 52-week low, which, combined with an RSI suggesting the stock is in oversold territory, could be of interest to value investors looking for potential entry points. Additionally, Teknova’s liquid assets surpass its short-term obligations, providing some assurance regarding the company's ability to meet its immediate financial liabilities.
Despite these potentially positive signals, it is important to note that analysts are not expecting Teknova to be profitable this year, and the company has been quickly burning through cash. These factors, paired with the recent poor stock performance, could be cause for concern and warrant careful consideration.
For investors seeking a deeper analysis, there are 10 additional InvestingPro Tips available at: https://www.investing.com/pro/TKNO. And for those interested in a subscription, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.